A phase 2 study of Vigil Neuroscience’s iluzanebart has missed its biomarker and efficacy endpoints, prompting the ...

SRM Institute of Science and Technology has released the SRMJEEE 2025 phase two schedule. Online registration concludes on ...

Disappointing results for iluzanebart come shortly after Vigil Neuroscience struck a buy-out deal with Sanofi, but analysts ...

The trial is expected to generate significant clinical data by late summer 2026. Allarity plans to pursue multiple advantaged ...

Corcept Therapeutics has tried to cast its recent phase 2 amyotrophic lateral sclerosis (ALS) failure in a more flattering ...

Disclosing new interim data from its Phase 1/2 AFFINITY DUCHENNE trial, Regenxbio (NASDAQ:RGNX) announced Thursday that its ...

Karnataka's cabinet has approved the establishment of Quantum Research Park phase-2 at IISc Bengaluru, with a government ...

Satellos Bioscience Chief Scientific Officer discusses early-stage trials of the company's Duchenne muscular dystrophy drug, ...

Phase 2 data expected in 2H 2026 - - KPL-387 Phase 1 single ascending dose data support profile for monthly dosing - LONDON, ...

Explore how the Air Force Safety Center's phase two of the Integrating Risk and Readiness campaign could empower airmen.

The Knoxville Community Development Corporation broke ground on Phase 2 of the Transforming Western initiative Wednesday.